Date: 2016-09-21
Type of information: Initiation of development program
phase:
Announcement: initiation of development program
Company: Cidara Therapeutics (USA - CA)
Product: CD201
Action
mechanism: immunotherapy product. CD201 has been selected with the Cloudbreak platform, which has been designed specifically to create compounds that direct a patient's immune cells to attack and eliminate bacterial, fungal or viral microbial pathogens. CD201 works by binding to a target present on a wide range of Gram-negative bacteria, including MCR-1, while simultaneously recruiting immune components to an infection site to coordinate localized host-mediated infection clearance. CD201 has demonstrated potent antibacterial activity in vitro against a number of clinically significant Gram-negative bacteria, including Klebsiella, Acenitobacter, Pseudomonas and Enterobacter spp. and resistant pathogens (including bacteria resistant to carbapenems and colistin), as well as pathogens harboring the mcr-1 plasmid. CD201 also has demonstrated preliminary efficacy and safety in a number of animal models of infection. This novel, bispecific antimicrobial immunotherapy is being developed for the treatment of multi-drug resistant (MDR) bacterial infections, including those caused by MCR-1 resistant pathogens.
Disease: multi-drug resistant (MDR) bacterial infections, including those caused by MCR-1 resistant pathogens
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On September 21, 2016, Cidara Therapeutics announced that the company has selected the first development candidate from its proprietary immunotherapy discovery platform, Cloudbreak™. The selected candidate, CD201, is a novel, bispecific antimicrobial immunotherapy being developed for the treatment of multi-drug resistant (MDR) bacterial infections, including those caused by MCR-1 resistant pathogens. The company expects to file an IND next year to initiate the clinical development of CD201. Cidara plans to continue ongoing investigations with Cloudbreak, with the intention of advancing multiple development candidates across different indications and therapeutic areas.
